You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry
|
|---|---|
| Published in |
Journal of Cancer Research and Clinical Oncology, August 2022
|
| DOI | 10.1007/s00432-022-04294-6 |
| Pubmed ID | |
| Authors |
Sena Valcarcel, Javier Gallego, Paula Jimenez-Fonseca, Marc Diez, Eva Martínez de Castro, Raquel Hernandez, Virginia Arrazubi, Ana Custodio, Juana María Cano, Ana Fernández Montes, Ismael Macias, Laura Visa, Aitana Calvo, Rosario Vidal Tocino, Nieves Martínez Lago, María Luisa Limón, Mónica Granja, Mireia Gil, Paola Pimentel, Lola Macia-Rivas, Carolina Hernández Pérez, Montserrat Mangas, Alfonso Martín Carnicero, Paula Cerdà, Lucía Gomez Gonzalez, Francisco Garcia Navalon, Mª Dolores Mediano Rambla, Marta Martin Richard, Alberto Carmona-Bayonas |
X Demographics
The data shown below were collected from the profiles of 17 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 12 | 71% |
| Unknown | 5 | 29% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 9 | 53% |
| Practitioners (doctors, other healthcare professionals) | 7 | 41% |
| Scientists | 1 | 6% |
Mendeley readers
The data shown below were compiled from readership statistics for 10 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 10 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 1 | 10% |
| Researcher | 1 | 10% |
| Student > Postgraduate | 1 | 10% |
| Unknown | 7 | 70% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 10% |
| Nursing and Health Professions | 1 | 10% |
| Medicine and Dentistry | 1 | 10% |
| Unknown | 7 | 70% |
Attention Score in Context
This research output has an Altmetric Attention Score of 17. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 July 2023.
All research outputs
#2,165,181
of 25,732,188 outputs
Outputs from Journal of Cancer Research and Clinical Oncology
#62
of 2,850 outputs
Outputs of similar age
#45,704
of 431,792 outputs
Outputs of similar age from Journal of Cancer Research and Clinical Oncology
#5
of 151 outputs
Altmetric has tracked 25,732,188 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,850 research outputs from this source. They receive a mean Attention Score of 3.8. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 431,792 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 151 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.